Prevention, Diagnosis & Treatment
Bayer’s brands treat and prevent conditions to improve quality of life.
June 19, 2019
Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) has opened enrollment for patients with...
June 04, 2019
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
Bayer today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company based in New Haven, Connecticut. The new life science research partnership uniquely leverages...
June 03, 2019
New data on Vitrakvi® (larotrectinib) in TRK fusion cancer patients with brain metastases or primary central nervous system (CNS) tumors
Bayer today announced results of a new analysis from clinical trials investigating Vitrakvi® (larotrectinib) in patients with TRK fusion cancer with primary central nervous system (CNS) tumors or...
Last Updated: September 19, 2018